Tekla Capital Management LLC Tcr2 Therapeutics Inc. Transaction History

Tekla Capital Management LLC

  • $2.53 Billion
  • Q2 2023

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022
SELL
$4.58 - $8.34 $1.08 Million - $1.97 Million
-235,808 Closed
0 $0
Q1 2021

May 14, 2021
BUY
$20.38 - $34.07 $4.81 Million - $8.03 Million
235,808 New
235,808 $5.21 Million

About TCR2 THERAPEUTICS INC.

TCRR Quotes by TradingView
  • Ticker TCRR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,606,400
  • Description
  • TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...
More about TCRR
Track This Portfolio

Track Tekla Capital Management LLC Portfolio

Follow Tekla Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tekla Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Tekla Capital Management LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email